Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short term Debt (2016 - 2025)

Historic Short term Debt for Northwest Biotherapeutics (NWBO) over the last 15 years, with Q3 2025 value amounting to $9.7 million.

  • Northwest Biotherapeutics' Short term Debt rose 513.43% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 513.43%. This contributed to the annual value of $9.6 million for FY2024, which is 424.47% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Short term Debt is $9.7 million, which was up 513.43% from $9.1 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Short term Debt peaked at $341.9 million during Q1 2021, and registered a low of $7.6 million during Q2 2024.
  • Moreover, its 5-year median value for Short term Debt was $9.6 million (2024), whereas its average is $78.0 million.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 272394.68% in 2021, then plummeted by 9143.06% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Short term Debt stood at $106.8 million in 2021, then decreased by 24.56% to $80.6 million in 2022, then tumbled by 88.59% to $9.2 million in 2023, then increased by 4.24% to $9.6 million in 2024, then rose by 0.91% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $9.1 million for Q2 2025, and $9.5 million during Q1 2025.